Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

Efficacy and safety of nivolumab for metastatic biliary tract cancer

(2019) Miaomiao Gou et al.   OncoTargets and Therapy

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

(2019) Angela Lamarca et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).

(2019) Richard D. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

(2019) Maeve A. Lowery et al.   CANCER

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

(2019) Makoto Ueno et al.   Lancet Gastroenterology & Hepatology

GenomicERBB2/ERBB3mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis

(2018) Maolan Li et al.   GUT

Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma

(2018) Richard Kim et al.   Oncotarget

625PDPembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study

(2018) M Ueno et al.   ANNALS OF ONCOLOGY

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

(2018) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Biliary tract cancer: current challenges and future prospects

(2018) Michele Ghidini et al.   Cancer Management and Research

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

(2017) Evan W Alley et al.   LANCET ONCOLOGY

New Horizons for Precision Medicine in Biliary Tract Cancers

(2017) Juan W. Valle et al.   Cancer Discovery

Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials

(2017) Manni Wang et al.   Drug Design Development and Therapy

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma

(2017) Jacqueline Fontugne et al.   Oncotarget

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue

(2016) Marisa Dolled-Filhart et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER